AASLD 2016 Biomarkers Define Future Age of Immunotherapy in Cancer

Biomarkers Define Future Age of Immunotherapy in Cancer
Marilyn White Published Online: Sunday, Nov 13, 2016

The use of immunotherapy as a treatment for cancer is progressively increasing with a flood of recent approvals for immune checkpoint inhibitors directed against CTLA-4 and PD-1. These therapies have revolutionized cancer treatment, making immunotherapy the fourth pillar of cancer treatment.“Immunotherapy is the perfect anti-cancer agent, more patients are being treated with immunotherapy and it continues to increase,” stated Drew Pardoll, MD, PhD, John Hopkins University, at the AASLD Liver Meeting. Discovering ways to look at patients’ endogenous immune systems can lead to treating patients with the right type of immunotherapy by targeting, detecting, and destroying cancer cells, which will be important as these approaches are explored in hepatocellular carcinoma (HCC).

Continue reading....

AASLD Updates @ OncLive

Dr. George N. Ioannou on the Efficacy of Antiviral Agents for Hepatitis C in HCC Patients

Dr. Gonzalez on Cost-Benefit of Treating Hepatitis C in HCC Patients Before Transplant

Lack of Screening, Surveillance Leads to Rising HCC Rates in Hepatitis B Patients

Hepatocellular carcinoma‎ incidence continues to rise among patients with hepatitis B despite improvements in antiviral therapies, stressing the importance of screening and surveillance in this population.

ERK Inhibition May Explain Regorafenib Success in Sorafenib-Resistant HCC

Efforts are under way to further evaluate the effects of regorafenib on sorafenib-resistant HCC cells, including the role of suppressing the ERK signaling pathway.